Holen Sie sich die Stockscreener-App
16.46
1.98%
0.32
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$16.14
Offen:
$16.44
24-Stunden-Volumen:
1.17M
Relative Volume:
0.98
Marktkapitalisierung:
$2.12B
Einnahmen:
$298.30M
Nettoeinkommen (Verlust:
$298.21M
KGV:
7.6073
EPS:
2.1637
Netto-Cashflow:
$166.93M
1W Leistung:
+3.85%
1M Leistung:
+5.51%
6M Leistung:
+3.46%
1J Leistung:
+107.83%
1-Tages-Spanne:
$16.21
$16.50
1-Wochen-Bereich:
$15.76
$16.50
52-Wochen-Spanne:
$7.285
$16.88
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
16.46 | 2.12B | 298.30M | 298.21M | 166.93M | 2.1637 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-07 | Hochstufung | Jefferies | Hold → Buy |
| 2025-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-05-05 | Eingeleitet | Cowen | Outperform |
| 2020-01-10 | Eingeleitet | Jefferies | Buy |
| 2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Bestätigt | FBR & Co. | Outperform |
| 2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
Understanding Momentum Shifts in (AUPH) - Stock Traders Daily
Aurinia Pharmaceuticals Stockanalyst focus and sector check at week’s end - AD HOC NEWS
Aurinia Pharmaceuticals Inc (AUPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Institutional Confidence - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum Rating - ChartMill
Aurinia Pharmaceuticals and Four More Stocks See Activist Action - Barron's
A Fresh Look At Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Consolidation - Yahoo Finance
Aurinia (NASDAQ: AUPH) director receives grant of 23,931 stock options - Stock Titan
Aurinia (NASDAQ: AUPH) director awarded 23,931 stock options expiring 2036 - Stock Titan
Aurinia Pharmaceuticals (AUPH) director receives 23,931 share option grant - Stock Titan
Aurinia (AUPH) director Jeffrey Bailey granted 23,931 stock options at $15.67 - Stock Titan
Avoiding Lag: Real-Time Signals in (AUPH) Movement - Stock Traders Daily
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million - AOL.com
AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors - Stocktwits
TANG KEVIN C's Strategic Acquisition in Aurinia Pharmaceuticals Inc - GuruFocus
Insider sales, option exercise at AUPH (NASDAQ: AUPH) reported - Stock Titan
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Tang group discloses 10% Aurinia (AUPH) stake plus $15 put options - Stock Titan
Strong shareholder support for Aurinia (NASDAQ: AUPH) board, auditor and say-on-pay - Stock Titan
AUPH: 25,000-share option exercise filed; Keenan sold 25,000 on 06/02/2026 - Stock Titan
Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow (NASDAQ:AUPH) - Seeking Alpha
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death - Business Wire
AUPH stock rallies after CEO shake-up: Retail bulls bet on turnaround - MSN
Aurinia Pharmaceuticals Insider Bought Shares Worth $12,455,227, According to a Recent SEC Filing - Moomoo
Insider Stock Purchases: June 03, 2026 - Quiver Quantitative
Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy - Benzinga
TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC. - marketscreener.com
Funds tied to Aurinia Pharmaceuticals (AUPH) add shares, sell put options - Stock Titan
Aurinia Pharmaceuticals(AUPH.US) 10% Shareholder Buys US$12.46 Million in Common Stock - Moomoo
25,000-Share Sale Notice for AUPH (NASDAQ: AUPH) - Stock Titan
AUPH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aurinia Stock Dips as Traders Eye Lupkynis Data - Bez Kabli
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Discipline and Rules-Based Execution in AUPH Response - Stock Traders Daily
AUPH News | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Aurinia (AUPH) Chief Legal Officer granted 115,541 performance stock units - Stock Titan
Aurinia Pharmaceuticals (AUPH) grants PSUs and stock options to CFO - Stock Titan
Aurinia (AUPH) COO receives 116,144 PSUs and 70,230 stock options - Stock Titan
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences - citybiz
Tranche Update on Aurinia Pharmaceuticals Inc.'s Equity Buyback Plan announced on February 15, 2024. - marketscreener.com
Why Aurinia Pharmaceuticals stock is surging Monday morning - MSN
Tangible book value per share of Aurinia Pharmaceuticals Inc. – FWB:IKAP - TradingView
Aurinia Pharmaceuticals stock (CA05156H1070): Q1 revenue beat and July earnings date in focus - AD HOC NEWS
Jefferies Upgrades Aurinia Pharmaceuticals (AUPH) - MSN
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):